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ABSTRACT
MicroRNAs (miRNAs) are noncoding RNA molecules
of 21 to 24 nt that regulate the expression of target
genes in a post-transcriptional manner. Although
evidence indicates that miRNAs play essential roles
in embryogenesis, cell differentiation and pathogen-
esis of human diseases, extensive miRNA profiling in
cells or tissues has been hampered by the lack of
sensitivecloning methods. Here we describe a highly
efficient profiling method, termed miRNA amplifica-
tion profiling (mRAP), as well as its application both
to mouse embryos at various developmental stages
and to adult mouse organs. A total of 77 436 Small-
RNA species was sequenced, with 11 776 of these
sequences found to match previously described
miRNAs. With the use of a newly developed compu-
tational prediction algorithm, we further identified
229 independent candidates for previously unknown
miRNAs. The expression of some of these candidate
miRNAs was confirmed by northern blot analysis and
whole-mount in situ hybridization. Our data thus
indicate that the total number of miRNAs in verteb-
rates is larger than previously appreciated and that
the expression of these molecules is tightly con-
trolled in a tissue- and developmental stage-specific
manner.
INTRODUCTION
MicroRNAs (miRNAs) are short noncoding RNA molecules
that inhibit gene expression through incomplete base
pairing with the 30-untranslated region (30-UTR) of target
mRNAs (1,2). The miRNA system is conserved from
worms to mammals and contributes to the regulation of a
wide variety of cellular functions. In Caenorhabditis elegans,
for instance, larval development is regulated by a set of
miRNAs that include members of the lin-4 and let-7 families
(3,4), and the function of Dicer1, which encodes an enzyme
essential for miRNA biogenesis, is indispensable for mouse
embryonic development (5). Furthermore, the miRNA
miR-181 has been implicated in the differentiation of
mouse B lymphocytes (6).
Evidence indicates that miRNAs also play a role in the
pathogenesis of human disorders including cancer. The
expression proﬁles of miRNAs are thus effective for classi-
ﬁcation of human cancers (7,8). Human let-7 miRNAs target
transcripts of the proto-oncogene RAS and are down-
regulated in a large proportion of lung cancer specimens
(9). Localization of miRNA genes to the fragile sites of
human chromosomes indicates that many more miRNAs
may be linked to carcinogenesis (10).
Although the recent public miRNA registry (miRBase
release 7.1 at http://microRNA.sanger.ac.uk) contains 326
entries for human miRNAs, a large number of additional
human miRNAs are thought to exist (11,12). Given the rela-
tion of miRNAs to cell growth and differentiation and to
human disease, it is important to compare the expression pro-
ﬁles of miRNAs (both known and unidentiﬁed previously)
among normal tissues and clinical specimens. Such studies
have been hampered, however, by the lack of sensitive clon-
ing methods for miRNAs. Current standard procedures for
miRNA isolation require several 100 mg of total RNA as a
starting material (13), an amount that is difﬁcult to obtain
from small tissues or clinical specimens. To overcome such
limitations, we have developed a highly sensitive cloning
method for miRNAs, which we have termed miRNA ampli-
ﬁcation proﬁling (mRAP).
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mRAP
A Small-RNA fraction was directly isolated from cells with
the use of a mirVana miRNA Isolation Kit (Ambion). In
our experience, the yield of Small-RNA with this kit was
about 40–50% of that for total RNA obtained by conventional
methods from the same number of cells. A portion of this
Small-RNA fraction together with size markers (19, 24 and
33 nt) was subjected to electrophoresis on a 15% polyacryl-
amide gel under denaturing conditions. The region of the
gel containing RNA of 19–24 nt was excised, and the RNA
molecules were recovered, dephosphorylated by incubation
for 30 min at 50 C with calf intestinal alkaline phosphatase
(New England Biolabs) and ligated to the 30 adaptor
[50-(Pu)uuAACCGCGAATTCCAG(idT)-30], where lower-
case letters indicate RNA, uppercase letters indicate DNA,
Pu denotes 50-phosphorylated uridine, and idT represents 30-
inverted deoxythymidine (Dharmacon). The ligated RNA was
subjected to reverse transcription with PowerScript reverse
transcriptase (Clontech) and the RT primer (50-GACTAG-
CTGGAATTCGCGGTTAAA-30) in the presence of the
50 adaptor (50-GACCACGCGTATCGGGCACCACGTATG-
CTATCGATCGTGAGATGGG-30). The products were amp-
liﬁed by PCR for 32 cycles of incubation at 95 C for 30 s and
65 C for 30 s with AmpliTaq Gold DNA polymerase
(Applied Biosystems), the 50 PCR primer (50-GCGTATCGG-
GCACCACGTATGC-30), and the 30 PCR primer (50-GAC-
TAGCTTGGTGCCGAATTCGCGGTTAAA-30). The result-
ing amplicons were fractionated by electrophoresis, and
those from 90 to 95 bp were eluted, digested with BanI
endonuclease (New England Biolabs), and subjected to
concatamerization with the use of a Ligation High Kit
(Toyobo, Osaka, Japan). Products from 500 to 2000 bp
were isolated by electrophoresis and cloned into the pGEM-
Teasy vector (Promega). A more detailed description of the
mRAP protocol is provided as Supplementary Data on the
NAR web site.
Prediction of novel miRNAs
Base calling and quality trimming of sequence chromato-
grams were performed with phred software (14). After mask-
ing of vector and adaptor sequences and removal of
redundancy, inserts of >18 bp were mapped to genomes
(ncbi35 assembly for human, ncbim34 assembly for mouse)
with the use of the megablast program in the NCBI software
suite (ftp://ftp.ncbi.nlm.nih.gov/blast). For every genomic
locus that matched an insert, repeat annotations were
retrieved from the Ensembl database (http://www.ensembl.
org) and repetitive regions were discarded. Genomic regions
containing inserts with 100 nt ﬂanking sequences were
retrieved from Ensembl, and a sliding window of 100 nt
was used to calculate RNA secondary structures with RNA-
fold software from the Vienna RNA Secondary Structure
Package (15).
To detect homologous hairpins in other genomes, we
performed a BLAST search with mature regions of each
RNA sequence against human, mouse, rat, dog, cow, opos-
sum, chicken, zebraﬁsh and fugu genomes. Hits of >20 nt
with an identity of >70% were extracted from the
genomes together with ﬂanking sequences of a size similar
to that observed for the original hairpins. Extracted
sequences were checked for hairpin structures with the use
of RNAfold, and positive hairpins were aligned with the
original hairpin with CLUSTAL W (16). For remaining
hairpins, randfold (17) values were calculated for every
sequence in an alignment by mononucleotide shufﬂing and
1000 iterations. A cutoff of 0.01 was used for randfold, and
only regions that contained a hairpin below this cutoff for
at least one species in an alignment were considered as can-
didates of miRNA genes. Berezikov et al. (18) describe the
computational method for prediction of miRNAs in more
detail.
Northern blot analysis
Small-RNA fractions (0.1 to 0.5 mg) were subjected to
electrophoresis on a 15% polyacrylamide gel under dena-
turing conditions, and the separated molecules were trans-
ferred electrophoretically to a Hybond-N nylon membrane
(Amersham Biosciences). The membrane was incubated
with
32P-labeled locked nucleic acid (LNA) corresponding
to mature miRNA sequences in ULTRAhyb-Oligo solution
(Ambion), and signals were detected with a BAS-1500
image analyzer (Fuji Photo Film).
Whole-mount in situ hybridization
Whole-mount in situ hybridization was performed as
described (19). LNA-modiﬁed oligonucleotides were synthes-
ized by Thermo Electron (Ulm, Germany), and digoxigenin
labeling was performed with a DIG Oligonucleotide 30 End
Labeling Kit (Roche Diagnostics, Penzberg, Germany).
RESULTS
Development of mRAP
To isolate miRNAs from small quantities of RNA, we ﬁrst
tried to amplify the miRNA fraction by incorporating simple
PCR steps into the conventional miRNA cloning procedures
(13). However, all such trials resulted in an ampliﬁcation of
non-speciﬁc products from degraded RNAs and adaptor-
primer concatamers without miRNA-derived cDNAs (as
shown in Figure 1A). To circumvent this limitation, we
invented the mRAP procedure by utilizing (1) the SMART
method (Clontech) for an efﬁcient cDNA ampliﬁcation and
(2) a long, sophisticated 50 adaptor. All nucleotide sequences
of the 50 adaptor originally invented by Lagos-Quintana (13),
SMART IIA oligonucleotide (Clontech), and a BanI site
(for a uni-directional concatamerization of PCR products)
were incorporated into our initial 50 adaptor sequence,
which was subsequently optimized by addition/removal of
nucleotides to reduce non-speciﬁc PCR products. In addition,
the length of the 50 adaptor (46 bases) was determined so that
the miRNA-derived products can be easily separated from the
two major byproducts (see Figure 1A).
In the mRAP procedure, isolated Small-RNA molecules
are ﬁrst ligated at their 30 end to a 30 adaptor and then
reverse-transcribed with the use of a primer (RT primer)
complementary to the 30 adaptor (Figure 1A). Because of
the fact that certain reverse transcriptases possess terminal
deoxynucleotidyl transferase activity a few nucleotides
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cDNA strand (20). After the annealing of a 50 adaptor to
the poly(C) overhang of the cDNAs, PCR is performed
with 50 and 30 PCR primers to exponentially amplify the
cDNAs. The isolated cDNAs are digested with the BanI
restriction endonuclease and self-ligated to generate conca-
tamers, which are then inserted into a plasmid vector for
nucleotide sequencing.
A
C
B
Figure 1. The mRAP protocol and its application to Jurkat cells. (A) Isolated Small-RNA molecules are ligated to the 30 adaptor (30-ADP) and subjected to
reverse transcription with the RT primer. After annealing of the 50 adaptor (50-ADP) to the poly(C) overhang at the 30 end of the synthesized cDNAs, the latter are
subjected to PCR with the 50 and 30 PCR primers. After an extensive cloning/sequencing of the PCR products, we noticed that, of the three major sizes of
amplicon generated, only the middle one includes cDNAs derived from miRNAs. The large product of  120 bp is composed of two 50 adaptors and one
30 adaptor without miRNA sequences. The small product of  70 bp is, on the other hand, composed of only one 50 adaptor and one 30 adaptor. The product of
 90 bp are thus isolated, digested with BanI, and self-ligated to yield concatamers. (B) Among 1652 mRAP clones of Jurkat cells that matched the human
genome sequence, 616 clones corresponded to known miRNAs, 17 are candidates for novel miRNAs and 219 corresponded to rRNAs, 166 to tRNAs, 127 to
transposable elements, 112 to simple repeats and 395 to other genomic sequences that do not fold into a hairpin or otherwise fail the miRNA prediction pipeline.
(C) Alignment of the nucleotide sequence (red) of one predicted novel miRNA (Hsj_43) with genomic sequences of human, chimpanzee, dog, mouse, cow, rat
and chicken. Nucleotides conserved between human and other species are shaded in gray. Possible base pairing schemes for the respective Hsj_43 precursors are
shown below the aligned sequences and, for the human sequence, in the upper inset.
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RNA fraction isolated from the human T cell line Jurkat. The
procedure readily generated >1 · 10
4 colony-forming units of
the concatamer library. A total of 958 clones was randomly
chosen from the library and subjected to nucleotide sequen-
cing. Each plasmid insert consisted of multiple short
cDNAs (average of 2.59 cDNAs per insert), and the dataset
contained a total of 2392 such cDNAs of >18 bp. The
1652 cDNA sequences that passed quality assessment
were subjected to computational screening for previously
unidentiﬁed miRNAs with an algorithm developed in-house.
In brief, after ﬁltering of repeat, rRNA, tRNA and small
nucleolar (snoRNA) sequences, the remaining sequences
predicted to fold into stable stem–loop structures were
selected and checked for overlap with known miRNA
genes (18).
As shown in Figure 1B, the Jurkat dataset contained 616
clones of known miRNAs (corresponding to 60 independent
miRNAs) and 17 clones of newly predicted miRNAs (corres-
ponding to 15 independent miRNAs) (see Supplementary
Tables S1 and S2). The proportion of miRNA clones
among our Jurkat cDNA sequences (38.3%) was slightly
smaller than that (46.9%) obtained by the conventional
method by Lagos-Quintana et al. (13).
One such candidate for the novel miRNA sequences
(‘Hsj_43’ according to our tentative nomenclature system)
is shown aligned with vertebrate genomes in Figure 1C.
The precursor of this miRNA is presumed to comprise 95
nt in human, and its nucleotide sequence is conserved
among various vertebrates and can fold into an incompletely
complementary hairpin structure (Figure 1C).
To determine whether mRAP is able to efﬁciently isolate
miRNAs from a small number of cells, we prepared a
Small-RNA fraction (7 mg, 700 and 70 ng, respectively)
from 1 · 10
6,1· 10
5 and 1 · 10
4 Jurkat cells. We found
that mRAP readily generated >1 · 10
4 colony-forming
units of concatamer libraries from all three samples (data
not shown). Nucleotide sequencing of randomly chosen
clones revealed that the most abundant hsa-miR-142-3p occu-
pies 36.6% (26 reads out of 71 total miRNA reads), 26.1%
(24 out of 92) and 20.0% (17 out of 85) of total miRNA
clones isolated from the 1 · 10
6,1· 10
5 and 1 · 10
4 cells,
respectively (data not shown). Similarly, another abundant
miRNA, hsa-miR-143, could be found in 11.3% (8 reads),
9.8% (9 reads) and 15.3% (13 reads) of miRNAs from the
1 · 10
6,1· 10
5 and 1 · 10
4 cells, respectively. The propor-
tion of isolated rRNAs was also constant among the samples,
indicating the high ﬁdelity of mRAP even when performed
with a small number of cells. These data conﬁrmed that
mRAP is highly sensitive for characterization of miRNA
proﬁles, needing <0.1% of the initial RNA quantity required
for current methods (13).
miRNA profiling of mouse embryos
We next applied mRAP to obtain miRNA proﬁles of mouse.
We ﬁrst isolated mouse embryos at 6.5, 7.5, 8.5, 9.5, 10.5,
11.5, 12.5, 13.5, 14.5, 15.5 and 17.5 days postcoitum (dpc)
and subjected them to miRNA proﬁling. A total of 25 944
small cDNAs was sequenced for all embryos (average of
2359 clones per embryo); 3362 of these clones corresponded
to 150 known miRNAs (miRBase release 7.1), and 198 of
them corresponded to 75 novel miRNAs (see Supplementary
Tables S3 and S4). These data indicated that many miRNAs
are expressed from an early stage of embryogenesis
(at 6.5 dpc, for instance, 9.63% of Small-RNA species corres-
ponded to miRNAs). Furthermore, novel candidate miRNAs
were detected throughout embryogenesis; the proportion of
novel miRNAs among all known and unknown miRNAs
was 6.54 ± 3.67% (mean ± SD) for the developmental stages
examined.
The expression proﬁles of miRNAs at each developmental
stage of the mouse embryo are summarized in Figure 2A and
Supplementary Table S3. Whereas some miRNAs, (such as
mmu-mir-124a) are expressed throughout embryonic devel-
opment, many others are expressed only at speciﬁc stages.
Expression of mmu-mir-206, e.g. was almost undetectable
up to 13.5 dpc but was increased markedly at 14.5 dpc and
thereafter. Expression of mmu-mir-148a was largely restric-
ted to 10.5 dpc, at which time it constituted 16.07% of all
miRNAs. Similarly, 24 cDNA clones (7.55% of all miRNA
species) derived from the mouse embryo at 7.5 dpc corres-
ponded to mmu-mir-23b, whereas only 0 to 3 such clones
were identiﬁed at other stages of development.
We performed Northern blot analysis to conﬁrm the
miRNA proﬁles identiﬁed by mRAP screening. As shown
in Figure 2B, northern analysis revealed that the expression
of mmu-mir-206 increased progressively with time of embry-
onic development, whereas that of mmu-mir-124a remained
relatively stable (with a slight increase apparent at 13.5 to
15.5 dpc). Direct comparison revealed that the temporal pro-
ﬁles of mmu-mir-206 expression determined by northern blot
analysis and by mRAP were similar, with a slight difference
in detection sensitivity (Figure 2C).
Northern analysis also detected the putative novel miRNA
Mmj_157 at an appropriate size and with preferential expres-
sion in mid to late stages of embryogenesis (Figure 2B). We
examined the localization of putative miRNAs in whole-
mount preparations of mouse embryos at 10.5 dpc by
in situ hybridization with LNA-modiﬁed DNA as a probe.
Some of the novel miRNAs were found to be expressed in
a tissue-speciﬁc manner. Both Mmj_163 and Mmj_157 putat-
ive miRNAs were detected speciﬁcally in the central nervous
system, with the former being preferentially expressed in the
telencephalon and the latter in the myelencephalon
(Figure 2D). Despite its abundance in the central nervous sys-
tem of embryos, we were not able to detect Mmj_157 in adult
brain (Figure 3A and Supplementary Table S5), indicating
that expression of this putative miRNA is both spatially and
temporally restricted. In adult mice, a substantial amount of
Mmj_157 was apparent only in the placenta, in which it con-
stituted 12.85% of all miRNA clones.
miRNA profiling of adult mouse organs
We next determined the miRNA proﬁles for 21 organs of the
adult mouse with the mRAP procedure. A total of 51492
clones derived from Small-RNAs (average of 2452 clones
per organ) was sequenced and found to include 8141 clones
of known miRNAs and 287 clones of novel candidate
miRNAs. The distribution of abundant miRNAs in each
organ is shown schematically in Figure 3A, with the complete
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miRNAs, including mmu-mir-124a and mmu-mir-143, were
found to be expressed ubiquitously among organs, whereas
many others were abundant in only a subset of organs, with
their relative expression (clone number) varying markedly
among such organs. Marked expression of mmu-let-7b, for
example, was apparent only in kidney, lung and ovary, and
the proportion of mmu-mir-382 among all miRNA clones
was >1% only in brain and placenta.
Candidates for novel miRNAs were found in the proportion
of 4.20 ± 4.75% (mean ± SD) of all miRNA species for
each organ. Similar to known miRNAs, expression of these
candidate miRNAs was found to be regulated in a tissue-
dependent manner (Supplementary Table S5). We did not
detect a correlation between the miRNA proﬁles and
germ-layer origins of organs.
Northern blot analysis conﬁrmed the organ-speciﬁc
expression of known and novel miRNAs in the adult mouse
(Figure 3B). Expression of Mmj_157 was found to be
restricted to the placenta and ovary, consistent with the
mRAP data (Figure 3C). Northern analysis revealed expres-
sion of mmu-mir-122a to be largely liver-speciﬁc (with a
low level of expression also apparent in stomach), again
consistent with the expression proﬁle obtained by mRAP
(Figure 3B and C).
DISCUSSION
We have thus developed a sensitive method for miRNA
proﬁling and have applied this method to obtain the ﬁrst
extensive miRNA proﬁles of the mouse. Our screening
identiﬁed 229 putative novel miRNAs (corresponding to
260 loci on mouse chromosomes). Sequence conservation
of our novel miRNA candidates among different species is
summarized in Supplementary Table S6. In compliance
with criteria for miRNA annotation, we require several
independent lines of experimental evidence (e.g. cloning
and northern blot analysis, or cloning from several libraries)
to deﬁne a novel miRNA as a bona ﬁde miRNA (21,22). If
experimental evidence is limited (e.g. cloned only from one
library), novel miRNAs are considered as candidates and
are annotated correspondingly (Supplementary Table S7).
It should be noted that, since three Gs are added to the
50-termini of miRNAs in mRAP (Figure 1A), it might be
difﬁcult to precisely determine the 50 ends of miRNAs
especially when the genomic sequence adjacent to mature
miRNAs contains Gs. Thus, it is possible that the nucleotide
sequences of our novel miRNA candidates in Supplementary
Tables S2 and S4 will contain inappropriate Gs at the
50-termini.
Although, we sequenced 77 436 mouse Small-RNA
species, many miRNAs were isolated only once in each tissue
or embryo (Supplementary Tables 3 and 5), suggesting that
the overall mouse miRNA catalog may not have been fully
revealed. Furthermore, given the stringent parameters in our
computational screening, it is possible that some bona ﬁde
novel miRNAs in our dataset were inappropriately dropped
at this in silico step. Screening for novel miRNAs by a
microarray approach with the same computational algorithm
identiﬁed a different, but partially overlapping, set of
A
B
D
C
Figure 2. Expression profiles of miRNAs in the mouse embryo. (A) The
percentage of each miRNA among the total miRNA population was
calculated for mouse embryos at the indicated stages of development (6.5
to 17.5 dpc). Abundant miRNAs are shown color-coded, with candidates for
novel miRNAs in red. (B) Northern blot analysis of the Small-RNA fraction
isolated from mouse embryos at the indicated developmental stages (9.5 to
17.5 dpc). The blot was probed with oligonucleotides specific for mmu-mir-
206, mmu-mir-124a or Mmj_157; a probe for U6 small nuclear RNA was
used as an internal control. Closed and open arrowheads indicate the positions
of 24 and 19 nt, respectively. (C) Expression level of mmu-mir-206 during
mouse embryogenesis as determined from the northern blot in (B) (red line)
and from the mRAP dataset (blue line). (D) Whole-mount in situ
hybridization of mouse embryos at 10.5 dpc with LNA-modified probes
specific for Mmj_163 or Mmj_157. Scale bar, 1 mm.
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for miRNAs in human clinical specimens by mRAP resulted
in the isolation of a set of candidate novel miRNAs that
include many with no mouse orthologs either in our dataset
or in the miRBase depository (S. Takada, Y. Yamashita,
E. Berezikov, Y.L. Choi, S. Fujiwara, M. Enomoto,
H. Hatanaka, H. Watanabe, M. Soda, R.H.A. Plasterk,
E. Cuppen and H. Mano, manuscript submitted). It is thus
likely that the mouse genome encodes additional miRNAs
yet to be discovered.
Isolation of novel miRNAs has been attempted to date
through a variety of approaches. Lagos-Quintana et al. (13)
compared miRNA proﬁles among mouse organs by a conven-
tional miRNA cloning procedure. They identiﬁed that three
miRNAs are expressed in a tissue-speciﬁc manner; mmu-
mir-1 in heart, mmu-mir-124a in brain and mmu-mir-122a in
liver, all of which is in a very good agreement with our obser-
vation (see Figure 3A and Supplementary Table S5). On the
otherhand,Baradetal.(23)choseoligonucleotidemicroarrays
to compare miRNA proﬁles among ﬁve human tissues. Again,
they revealedatissue-speciﬁcexpressionofhsa-miR-122aand
hsa-miR-124a, which matches our results.
Mineno et al. (24) recently analyzed miRNA expression
with the massively parallel signature sequencing (MPSS)
technology among three developmental stages (9.5, 10.5
and 11.5 dpc) of mouse embryo. Many of their ‘top 20
miRNA signatures’ can be observed in our dataset. For
instance, their result reveals that the expression of mmu-
mir-199a was increased from 9.5 to 11.5 dpc of mouse
embryo. Our data demonstrates that the augmentation of
mmu-mir-199a expression further continues to 15.5–17.5
dpc (Supplementary Table S3) of embryo. Similarly, both
of our and Mineno’s data indicate that mmu-mir-19b is
abundantly expressed at 9.5–11.5 dpc of mouse embryo (Sup-
plementary Table S3). Additionally, one of the abundant
novel miRNAs in our embryo dataset, Mmj_157, was also
counted for many times as miRNA426 in the data of Mineno
et al. There may be, however, some difference between these
two datasets. One of the highly expressed miRNAs in mouse
embryo, mmu-mir-124a, in our data are missed from that of
Mineno et al. Our northern blot analysis in Figure 2B
supports the expression of mmu-mir-124a in embryo.
To directly compare our mRAP data with those by other
high-throughput methods, we then hybridized RNA from
AB
C
Figure 3. Expression profiles of miRNAs in adult mouse organs. (A) The percentage of each miRNA among the total miRNA population was calculated for the
indicated organs of the adult mouse and is shown schematically as in Figure 2A. PB MNC, peripheral blood mononuclear cells. (B) Northern blot analysis of the
Small-RNA fraction from the indicated adult mouse organs with probes specific for the indicated RNA species. (C) Expression levels of Mmj_157 or mmu-mir-
122a in adult mouse organs as determined from the northern blot in (B) and from mRAP data.
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Vedbaek, Denmark) to quantitate miRNA amounts. Hsa-
miR-142, the most abundant miRNA in our Jurkat dataset
(Supplementary Table S1), was indeed identiﬁed as one of
the strongest signals in the array data (data not shown). How-
ever, with regard to another abundant miRNA hsa-miR-143
in our dataset, the microarray could give a hybridization
signal only at the intensity of backgrounds (data not shown).
Northern blot analysis clearly conﬁrmed the expression of
hsa-miR-143 in Jurkat cells (Supplementary Figure S1), sup-
porting our mRAP data. Caution should thus be taken to estim-
ate the miRNA proﬁles based on some type of microarrays.
We also quantitated the expression level of mmu-mir-122a,
mmu-mir-185 and let-7-a with the TaqMan MicroRNA assay
(Applied Biosystems) in mouse brain, liver and heart. Relat-
ive expression intensity of mmu-mir-122a to that of let-7-a
was 1.056 · 10
 4 for brain, 7.227 for liver and 1.230 ·
10
 4 for heart, indicating the liver-speciﬁc expression of
mmu-mir-122a. On the other hand, the TaqMan assay
revealed a weak but ubiquitous expression of mmu-mir-
185; its relative expression level to that of let-7-a was
5.759 · 10
 3 for brain, 3.816 · 10
 3 for liver and 6.769 ·
10
 3 for heart. Both of these data are highly compatible
with our dataset (Supplementary Table S5).
Given that mRAP is able to provide an miRNA proﬁle with
asfewas1·10
4cells,itopensupthepossibilityofdirectchar-
acterization of miRNAs in small amounts of tissue, such as
thoseavailableformouseembryos(asdemonstratedinthepre-
sent study) and fresh human specimens. Indeed, with mRAP,
wehavecharacterizedmiRNAproﬁlesevenforsmallpapillary
muscles of the human heart ventricle (S. Takada, R. Kaneda,
E. Berezikov, Y. Yamashita, Y.L. Choi, S. Fujiwara,
M. Enomoto, H. Hatanaka, H. Watanabe, M. Soda,
R.H.A. Plasterk, E. Cuppen and H. Mano, manuscript submit-
ted). Our present miRNA proﬁling in mouse has shown that
such proﬁles vary markedly among tissues and developmental
stages. An important application of mRAP will be determina-
tion of whether expression of miRNAs is associated with
human disease by analysis of fresh human tissue specimens.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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